- Investor's Business Daily•2 hours ago
Gilead, Amgen and AbbVie underperformed in Q4, Leerink analyst Geoffrey Porges predicted Monday.
- Barrons.com•6 hours ago
Gilead Sciences (GILD) reports earnings on Feb. 7--which means that analysts everywhere are trying to predict what its numbers and guidance might look like. Last week, RBC's Michael Yee and team noted that "visibility is tough on Hepatitis C right now," and today Credit Suisse analyst Alethia Young and team note their agreement: Gilead- we think it will be difficult for the company to guide the HCV business as patient starts remain difficult to forecast. Numbers have come in for Gilead which helps for the set up into the guidance announcement.
- Motley Fool•6 hours ago
And what does that mean for the stock long-term?
GILD : Summary for Gilead Sciences, Inc. - Yahoo Finance
Gilead Sciences Inc. (GILD)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||70.76 x 700|
|Ask||70.77 x 900|
|Day's Range||70.30 - 71.29|
|52 Week Range||70.30 - 103.10|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||6.54|
|Dividend & Yield||1.88 (2.65%)|
|1y Target Est||N/A|